Registration With and Without International Quality Certificates

1. Key takeaways

The Egyptian registration guidelines split into two main tracks according to whether international quality certificates are held. Imported devices and local devices holding international quality certificates such as CE and FDA fall under EDREX: GL.CAMD.002 (September 2025, Version 2). Locally produced devices not holding international quality certificates fall under EDREX: GL.CAMD.09 (September 2025, Version 2), whose distinctive feature is that the Medical Devices Inspection Department draws samples from the trial production batch and sends them to EDA laboratories or other EDA-accredited institutions for analysis. This dividing line determines the evidence pathway, not the product risk class. Choosing the track is therefore not a strategic preference but a mechanical consequence of the certificate situation, and the choice cascades directly into timelines, document lists, and committee exposure.

2. Legal basis

3. Expert insights

Insight 1: the core difference between holding and not holding certificates is who supplies the evidence.

Where international quality certificates are held, the principal evidence of safety and performance comes from external conformity assessment results such as CE and FDA certificates, and the work of the EDA is to verify those results and to supplement local requirements, including stability, biocompatibility, and Arabic labeling. Where no certificate is held, the evidentiary gap must be filled by local testing: GL.CAMD.09 provides expressly that the Medical Devices Inspection Department samples from the trial production batch for analysis. The burden of proof does not disappear on the no-certificate track; it is relocated from a notified body or foreign authority to the manufacturer and the Egyptian laboratory system.

Insight 2: the no-certificate pathway has a different timeline structure.

The process nodes of GL.CAMD.09 run as follows: feedback of the acceptance result within 10 working days of platform submission; document evaluation against the checklist; a request for corrections issued within 20 working days; evaluation of the corrections within 10 working days of resubmission; and then evaluation by the dedicated Scientific Committee and by the stability and biocompatibility committee. Compared with the 5 or 3 working days acceptance feedback under GL.CAMD.002, the acceptance feedback window on the no-certificate track is longer, and the sequence contains two committee evaluations that the certificate track may not require. Planning templates must therefore be built per track, not per product family.

Insight 3: the no-certificate pathway is by no means a low-requirements pathway.

Quite the opposite: the no-certificate pathway requires submission of an analysis dossier and passage through two technical evaluations, namely the dedicated Scientific Committee and the Stability and Biocompatibility Evaluation Committee. The absence of an external certificate does not lower the intensity of technical review; it shifts the burden of proof back onto the company itself and onto local testing. Companies that read the no-certificate track as a shortcut usually discover that it is the longer and more expensive road once sampling, committee scheduling, and laboratory cycles are priced in.

Insight 4: a local factory holding a CE certificate enjoys document simplification.

By an announcement issued on April 16, 2026, the EDA provided that local factories holding CE certificates are, when submitting registration or re-registration dossiers, exempt from submitting the reference-country free sale certificate (FSC), stability study reports, and biocompatibility test reports, with the EDA reserving the right to require them where necessary. This makes the combination of local production plus a CE certificate the configuration with the lightest document burden currently available in Egypt. For manufacturers weighing localization, the CE investment now yields a double return: market access in reference countries and a simplified Egyptian dossier.

Insight 5: a common mistake among foreign manufacturers is attempting to use the no-certificate pathway to avoid the reference-country FSC.

The no-certificate pathway applies only to locally manufactured devices, since the registration applicant under GL.CAMD.09 is the local manufacturer or its scientific office. Imported devices cannot use it. The idea of setting up local production to bypass the reference-country FSC lands the product in sampling-based testing and dual-committee evaluation, a cost that generally exceeds simply obtaining the reference-country FSC. The bypass logic should be tested against the full timeline before it is adopted, and in most cases it will fail that test.

4. Practical recommendations

1. First determine whether international quality certificates are held: CE, FDA, and similar certificates are the first variable in the choice of pathway.
2. Reserve sampling time for local products without certificates: the inspection department draws samples from the trial production batch, so a trial production batch must exist before filing.
3. Check the timelines by pathway: on the no-certificate pathway, expect acceptance feedback within 10 working days, a correction request within 20 working days, and correction evaluation within 10 working days.
4. Prioritize obtaining CE for local factories: with CE, the April 2026 announcement exempts the FSC, stability study, and biocompatibility reports from the dossier.
5. Do not treat local manufacturing as a shortcut around the reference-country FSC: it converts the product onto a heavier evidentiary pathway.
6. Prepare the analysis dossier: the no-certificate pathway requires an analysis dossier containing the required documents and annexes, so assemble it before submission.

5. Verification checklist

• □ Determined whether the product holds international quality certificates
• □ Identified the applicable guideline as GL.CAMD.002 or GL.CAMD.09
• □ On the no-certificate pathway, arranged the trial production batch and the sampling plan
• □ Checked the acceptance and evaluation timelines for the chosen pathway
• □ Evaluated the feasibility of obtaining a CE certificate for the local factory
• □ Assembled the documents and annexes required for the analysis dossier on the no-certificate pathway

Regulatory information verified as of October 29, 2026. The pathway division described in this article follows the current texts of EDREX: GL.CAMD.002 and GL.CAMD.09 and the EDA announcement of April 16, 2026; when the guidelines are revised, the content must be re-checked.

• Local Egypt support: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval, and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant structure (importing company, local factory, or scientific office), preparation for Scientific Committee evaluation, advisory work on pathways for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the build-out of vigilance systems and periodic reporting.
• Service capabilities: product characterization and risk classification (devices Class I–III and IVDs Class A–D), registration and re-registration, determination of applicability of system registration and group registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.